Epizyme, Inc. (NASDAQ:EPZM)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Monday.
EPZM has been the topic of a number of other research reports. BidaskClub downgraded Epizyme from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Royal Bank Of Canada set a $20.00 price target on Epizyme and gave the stock a “buy” rating in a research report on Monday, June 12th. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Tuesday, May 16th. Cann reissued an “outperform” rating and set a $26.00 price target on shares of Epizyme in a research report on Wednesday, April 12th. Finally, Wedbush reissued an “outperform” rating and set a $24.00 price target on shares of Epizyme in a research report on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $23.75.
Shares of Epizyme (EPZM) opened at 13.50 on Monday. Epizyme has a 12-month low of $7.02 and a 12-month high of $18.50. The firm’s market cap is $787.83 million. The firm has a 50-day moving average price of $13.88 and a 200-day moving average price of $14.28.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. The firm had revenue of $10 million for the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative return on equity of 58.97% and a negative net margin of 1,376.33%. The business’s revenue was up 2027.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.49) earnings per share. Equities research analysts anticipate that Epizyme will post ($2.43) EPS for the current year.
In related news, insider Robert A. Copeland sold 2,500 shares of the stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $13.45, for a total transaction of $33,625.00. Following the sale, the insider now owns 34,038 shares of the company’s stock, valued at $457,811.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $16.11, for a total value of $241,650.00. Following the sale, the insider now directly owns 22,228 shares in the company, valued at approximately $358,093.08. The disclosure for this sale can be found here. Insiders sold 50,524 shares of company stock worth $746,797 in the last ninety days. 25.20% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of EPZM. Legal & General Group Plc increased its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of Epizyme during the first quarter worth about $175,000. BB&T Securities LLC bought a new stake in shares of Epizyme during the second quarter worth about $181,000. Trexquant Investment LP bought a new stake in shares of Epizyme during the second quarter worth about $184,000. Finally, SG Americas Securities LLC increased its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares in the last quarter. 81.30% of the stock is currently owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
